Panion & Bf Biotech Inc. · TWSE:1760

Panion & Bf Biotech — Investor Presentation (June 2026)

70 slides from Panion & Bf Biotech's investor presentation, Jun 25, 2026

Slide 1: Health, Sharing, and Care
寶齡富錦生技 (1760.TT) Health, Sharing, and Care – Innovative healthcare solutions for a better life Copyright © PANION & BF BIOTECH INC.
Slide 2: Disclaimer
Panion & BF Biotech Inc. (The Company) Disclaimer  The presentation and the relevant information mentioned in this material, including operating performance, financial performance and the business outlook, have been compiled from both internal and external resources.  These forward looking stateme
Slide 3: Panion & BF Biotech Inc.
Panion & BF Biotech Inc. • Establishment：January 7, 1976 in Taipei Taiwan. • IPO Date：January 23, 2018 on Taiwan Stock Exchange Main Board (Ticker : 1760) • Integration Capability：Vertical Integration Converting R&D, Manufacturing, Branding, Channel Marketing, and Diversification. • Diversified Busi
Slide 4: Content
目錄 Content 營運成果 (Operation Highlights) 財務報告 (Financial Statements) • 永續發展報告 (Sustainability Development) 各事業體的發展 (Key Business Units and Outlook) Q&A
Slide 5: Content
目錄 Content 營運成果 (Operation Highlights) 財務報告 (Financial Statements) • 永續發展報告 (Sustainability Development) 各事業體的發展 (Key Business Units and Outlook) Q&A
Slide 7: Consolidated financial results 2023-2026 Q1
Bier a ihia re 2023-20264F:1-3 2,500,000 2,000,000 1,500,000 1,000,000 500,000 0 | 20234F. 202448 20254F. 202646:1-35 BEACH EET mR ANST] mw ASF Hifi: MAMI 202346 202442 202546 20264F.1-3F ese ARH 1,881,875 2,029,645 2,063,392 519,291 EA 974,397 1,060,437 1,116,851 269,380 ARAL SF 168,711 217,435 294
Slide 8: Revenue by segment
SHE HBR 300,000 2023-20264F:1-3R 200,000 70,000 «00,000 se0,000 400,000 2c0,000 200,000 all = _ —_——_ Et) ene SRS sath wi¢th (#1) “a 202344 mw 20244 m20254¢ mw 20264F1-38 Mtr: MONTE Haar) Sti ftdh {enti Wels bist Eval BRE SLGED eat 20234F 740.492 | 39%} 295.732 | 16%] 219.255 | 12%] 405.235 | 22%] 8
Slide 9: 2026 Q1 vs 2025 Q1 comparison
Bohr Gia soonmn 20264F:1-3 5 FalgAtL . : L I CO BRR BREF BRAT PFI AMF] mw 20254F1-3A(A) mi 20264F1-3 5 (B) HALE IETE 2261-3 202541-3 (A) | 20264F:1-35(B) Faye 21351 cca) | REAM BUA 481,532 519,291 37,759 8 BEAL 262,052 269,380 7,328 3 RBA 54,547 80,599 26,052 | 48 BAL 28,200 51,743 23,543 | 83 Ae Ri
Slide 10: Q1 revenue by segment
SHE MASA 2026481-3 5 IBALL scoooo “ a iz | | = = oe (bite Pret aes ales eae BUH RE) m 20254¢1-3 (A) m 20264#:1-3A(B) tir: RON T festa Eta ttt {bittds Beetles RBA ate Fhe) Gat 20254¢:1-3F(A) | 171,015 | 36%] $7,211 | 18%] 47,208 | 10%| 116,253 | 24%] 28,203] 6%| 27,663} 6%] 3.979 | 0.8%| 481,532 |100
Slide 12: 2025 greenhouse gas inventory
2025年度溫室氣體盤查依循標準 • 國際標準：ISO 14064-1: 2018 組織與報告邊界 • 盤查期間： 2025/01/01 ～ 2025/12/31。 • 營運邊界：採營運控制法，全面盤查集團內外共 8 個廠址。台灣母公司：包括台北總公司、平鎮廠、龍潭研發中心、汐止廠（含二廠與三廠區）子公司：正峰化學製藥大園廠(台灣)、珠海廠(中國) 變動據點：汐科廠（營運至 2025/04/30，後併入平鎮廠）第三方查證機構 • BSI (英國標準協會)進行查證，類別1 與類別2 達到最高標準的合理保證等級。 2026/03~04 2026/06/04 2026/06/16 2026/
Slide 13: 2025 sustainability report
2025年度永續報告書報告書編製標準與亮點 • 國際接軌標準：依據 GRI 2021 核心標準、SASB 醫療保健（生物技術與製藥）行業分類編製。股東及 • 法令遵循：遵循「公司治理 3.0 - 永續發展藍圖」及證交所作業辦法。 • 核心內容：彙整 2025 年公司治理、經濟、產品服務、環境與社會等各面向投資人之具體成果與數據，將揭露於公開資訊觀測站及官網。報告範疇與報導期間供應商員工 • 報導期間： 2025/01/01 ～ 2025/12/31。 • 涵蓋範疇：台灣母公司：包括台北總公司、平鎮廠、龍潭研發中心、汐止廠（含二廠 2025年度與三廠）利害關係人子公
Slide 14: IFRS sustainability disclosure adoption
IFRS永續揭露準則及導入 • 依主管機關規定，資本額未滿 50 億元之上市公司:本公司屬第三階段導入企業 • 寶齡富錦攜手KPMG推動及導入IFRS永續永續揭露準則（S1及S2 )。此將於 2029 年正式適用及發布，採 IFRS 永續揭露準則揭露之 2028 年永續資訊。同時納入股東會年報【永續專章】。全面性落差分析建構完整永續策略藍圖強化資訊揭露公信力透過KPMG會計師事務所的專由 KPMG 專業團隊協助，針結合公司「生技醫療」核心本業與深入輔導，優化永續報告對現行「環境(E)」、「社會業，量身打造中長期減碳路徑書（GRI/SASB）之數據搜集 (S)」、「治理(G)
Slide 16: PBF growth framework: three growth engines
PBF 成長架構：由既有基礎，發展三支劍以學名藥與感控事業為基礎，持續投入研發與資本，延伸至新藥& API、檢驗、醫美三大成長引擎 Copyright © PANION & BF BIOTECH INC.
Slide 17: PBF healthy longevity strategy
從研發布局到長期價值：PBF 健康壽命策略推進 17
Slide 18: PBF healthy longevity strategy
(ie it 28 Th 2 AASB : PBF R@ER SS on RABE SE rh | >
Slide 20: Nephoxil China Approval
Nephxoil® China Approval: Achievement & Key Breakthrough 里程碑與關鍵突破原預計於第三季度取得藥品上市許可，在多方整合加速下提前於4月底獲批，在未額外執行中國ＰＤ患者臨床試驗的情況下，透過法規科學證據整合及監管機關持使本新藥得參與2026年度國家醫保目錄(NRDL)申報作業，加速市場滲透與放量時程。續溝通，成功取得涵蓋ＨＤ及ＰＤ患者之全適應症核准，近一步擴大市場機會。 NMPA approval was obtained ahead of schedule in April 2026 (originally anticipated
Slide 21: China Market Potential
China Market Potential 中國市場發展狀況 World largest dialysis population 潛在總透析人口估計為二至三百萬人 Source: Chinese National Renal Data System (CNRDS). 19th Conference on Critical Care Nephrology & Blood Purification,Chinese Society of Nephrology, 2025. 21
Slide 22: Business Model Evolution
Business Model Evolution Royalty based + Asia Pacific commercialization platform 22
Slide 23: Ferric Citrate Japan
Ferric Citrate Japan Japan Ferric Citrate Sales Riona® 250 tablets ¥9,000 ¥8,000 • 2025: 8,479 million Yen, YOY 4% ¥7,000 growth Sales in Million Yen ¥6,000 • 2026Q1: 1861 million yen, YOY 4.7% ¥5,000 growth ¥4,000 ¥3,000 • To date no generic drug application has ¥2,000 been approved for Riona Table
Slide 24: Ferric Citrate USA
Ferric Citrate USA US Ferric Citrate Sales Auryxia® 1000 Tablets $200,000 $180,000 • 2025 net sales achieved US$178M, due to $160,000 CMS bundled payment and qualified for Sales in thousand USD TDAPA $140,000 $120,000 • 2026Q1: US$36.2M, lower than 2025 due to price competition. $100,000 • In additi
Slide 25: Asia Pacific Market Expansion
Asia Pacific Market Expansion FEXENOL® Generation I 第1代 Generation II 第2代 ESRD Dialysis 末期腎病透析市場 CKD 3-5 慢性腎病市場 NEPHOXIL 500 mg capsules FEXENOL 1000 mg tablets • KOREA: >100,000 dialysis patients. • TAIWAN: 2.6 million CKD patients LG Chem 2026 maintains expansion 1) Late stage NDA review targeting
Slide 26: New Drug Pipeline
New Drug Pipeline 新藥開發進行中 Pre Clinical Phase I Phase II Phase III PBF-501 AR inhibitor for Acne • Acne, Androgen Receptor Inhibition 雄性素受體抑制之痤瘡治療新藥 505(b)(2) • Secured 8 Patents Across 7 Major Markets | 已取得台、美、中、歐等七國共八項專利 • Formulation optimization and IP development PBF-502 ED Tri-Combo • Patented
Slide 27: PBF healthy longevity strategy
從研發布局到長期價值：PBF 健康壽命策略推進 27
Slide 28: Diagnostic Division
江政儒創新診斷事業處 Ken Chiang, Diagnostic Division
Slide 29: IVD Development Status 2025-2027
IVD開發進度 IVDDevelopment Status 2025~2027 開發送件核准 2025 2026 2027 2028 H1 H2 H1 H2 H1 H2 H1 H2 退伍軍人菌抗原快篩試劑 1 Legionella pneumophila Ag 困難梭菌抗原快篩試劑 2 Clostridioides difficile Ag 呼吸道三合一抗原快篩家用 3 Res 3 Flu AB & COVID Ag Self Test iFOB&HP抗原快篩試劑 4 FOB & HP Ag Adeno&Rota&Noro抗原快篩試劑 5 Adenovirus & Rotavirus &
Slide 30: Global IVD Approval Status
2025全球IVD許可證概況 Global Approval Status Canada 1 US 5 Taiwan 18 Guatemala 3 Thailand 1 Singapore 2
Slide 31: Pathogens of various kinds
呼吸道病原 Respiratory Pathogen  新型冠狀病毒 (Sars-Cov-2)  流感病毒(Influenza Virus)  呼吸道融合病毒(RSV) 其他病原Others  腺病毒(Adenovirus)  A型鏈球菌(GAS)  B型鏈球菌(GBS)  嗜肺性退伍軍人桿菌(L. pneumophila)  登革熱病毒(Dengue Virus)  肺炎鏈球菌(S. pneumoniae)  屈公病病毒(Chikungunya Virus)  肺炎黴漿菌(M. pneumoniae)  B型肝炎病毒(HBV)  人類間質肺炎病毒(hMPV)  C
Slide 32: Signals in the blood
癌症指標全血細胞分析 Cancer Marker Complete Blood Count 發炎指標  RBC  WBC  PLT  CA125 Inflammation Marker  CA15-3  Hb  HCT  Neut%  Lymph%  MPV  PDW  前降鈣素(PCT)  CA199  MCV  Mono%  PCT  MCH  Eos%  C反應蛋白(CRP)  PSA  MCHC  Baso%  介白素6號(IL-6) Signals in the blood 心臟指標血液生化檢驗 Cardiac Marker Bioc
Slide 33: Shortage of healthcare providers
2 AE SO be SRA Shortage of healthcare providers
Slide 34: Decentralization
APUIME Decentralization
Slide 35: Point of Care Test and Self Test
Ae aes an te Bi =a Point of Care Test Self Test = IN CARE CENTER HOME e rel 4x on) Ce] we mest Fh RR eat Clinics Senior Care Center Home-based Medical Care
Slide 36: Diagnostic Delay and Comorbidities
aD lan WE + js A Fel Diagnostic Delay Duration of Comorbidities
Slide 37: Diagnostic delay and comorbidity by disease
診斷延遲的定若診斷延遲 → 疾病延遲比例 / 時間來源關聯性說明義典型共病/併發症疫情早期（2020）平均 - 急性呼吸窘迫症候群 (ARDS) 若延遲診斷 → 無法及早給出現症狀 → Lancet Public COVID-19 4–7 天；後期因快篩普 - 血栓、心肌炎予抗病毒藥或抗凝劑，肺纖確診 PCR Health 2021 及縮短到 1–2 天 - 長新冠 (Long COVID) 維化與血栓共病提早出現傳統 PCR 需 1–3 天；因若錯過抗病毒藥的「48 小發病 → - 繼發性細菌性肺炎此診斷延遲常造成抗病 J Clin Virol 時黃金期」，肺炎
Slide 38: Streamline the workflow from diagnosis to medical decision
Streamline the workflow from diagnosis to medical decision! tEFt tee reales Fs SRR AY RL
Slide 39: Detection technology platforms
aD r ) | F NIA M 1 Ewop CLIA COLORIMETRY Op ical Scattering Microfluidics ELISA Electrical Impedance Multiplex CLOUD Hot Spot Analysis Ale iol
Slide 40: NANA HT (prototype)
NANA HT (prototype) Ip NANA Ystrip NANA . NANA S1 Ys! Res3 FUAB& COVO-D Cal Cl A = 3 stp] {FOB & H. pylori
Slide 41: Self-applied blood collection device
Self-Applied Caplin | Blood Collection Devieg For decentralized POCT sampling lt € in cal aie No venipuncture fe) required (any Saal) \ A News = ’ a ~ 0.5-1.5 mL 1 de es sample volume a e - Neu en fg Homes Mill PocTworkons mote cal | rel - Nee ee — ¢ ~~ « fo} a (@mnen) a Home Testing J, ~— = ‘ e a
Slide 42: VSTRIP respiratory panel
[ VSTRIP™ 5 IN 4 RESPIRATORY PANEL COVID-19 (NecaTive — RSV (necarive ao wom —— Adenovirus (wecarive ——_—_—_————
Slide 43: Application Scenario
i j (5 1 Application Scenario fe se Bh ee POC Medical Services $e Ft BS AD Strengthen Tiered Healthcare $2 Ft Bil 5S BS Expand Home-Based Healthcare $27 SB BD tt Enhance Healthcare Resilience i) tt AE Reduce Antibiotic Overuse ah 2) 5D Ee HEI Reduce Diagnostic Delays m JAE SHome Care | Residential C
Slide 44: Clinic-Based POCT
診所即時檢測 Clinic-Based POCT  上呼吸道檢測Respiratory Infection Testing  抗生素管理Antibiotic Stewardship 44
Slide 45: Clinic-Based POCT
Clinic-Based Point-of-Care Testing 診所即時檢測 Clinic-Based POCT  慢性病管理Chronic Disease Management
Slide 46: Home-Based Care
到宅醫療 Home-Based Care  到宅 POCT 檢測At-Home POCT  長照與高齡監測Elderly & Long-Term Care Monitoring  感染與急性症狀評估Infection & Acute Symptom Assessment
Slide 47: Disaster Medicine & Humanitarian Aid
災難醫療&人道救援 Disaster Medicine & Humanitarian Aid  現場快速分流On-site Rapid Triage  傳染病群聚監測Infectious Disease Cluster Monitoring  慢病與高風險追蹤Chronic Disease & High-Risk Follow-up
Slide 48: Public Health Trend Analysis
公衛趨勢分析 Public Health Trend Analysis  傳染病熱點監測Infectious Disease Hotspot Monitoring  區域風險預警Regional Risk Alerts  公衛決策與資源配置Decision-Making & Resource Allocation 48
Slide 49: Public Health Trend Analysis
公衛趨勢分析 Public Health Trend Analysis  傳染病熱點監測Infectious Disease Hotspot Monitoring  區域風險預警Regional Risk Alerts  公衛決策與資源配置Decision-Making & Resource Allocation 49
Slide 50: Public Health Trend Analysis
公衛趨勢分析 Public Health Trend Analysis  傳染病熱點監測Infectious Disease Hotspot Monitoring  區域風險預警Regional Risk Alerts  公衛決策與資源配置Decision-Making & Resource Allocation 50
Slide 51: Home Testing & Health Monitoring
居家檢測與健康監控 Home Testing & Health Monitoring  預防醫學與健康管理Preventive Medicine & Health Management  居家感染檢測Home Infection Testing  居家慢病追蹤Home Chronic Disease Monitoring  出院後追蹤Post-Discharge Follow-up
Slide 52: Our POCT Ecosystem
OUR ECOSYSTEM 1. RAPID DETECTION POCT test kits High sensitivity Easy to use > POCT DIAGNOSTICS ECOSYSTEM From Rapid Detection to Data Intelligence, Empowering Health Everywhere. 2. POCT CONNECTIVITY POCT devices ‘Auto data capture Secure transmission i. 3. CLOUD PLATFORM Data upload & management Re
Slide 53: Test reagents, instruments, data management
檢驗試劑檢驗儀器數據管理 Test Instruments Data Management Reagents  病原檢測Pathogen Detection  疾病診斷Disease Diagnosis  生物標記檢測Biomarker Detection  療效評估Treatment Monitoring  細胞檢測Cell Detection  疾病預測Disease Prediction / Prognosis  健康管理Health Management  基層醫療單位Primary Care Facilities  醫學中心Medical Centers  家
Slide 54: Diagnosis within minutes
Diagnosis within 30 min 307A Sera
Slide 55: Streamline the workflow from diagnosis to medical decision
Streamline the workflow from diagnosis to medical decision! tEFt tee reales Fs SRR AY RL
Slide 56: VstriO AGE
VstriO AGE
Slide 57: PBF healthy longevity strategy
從研發布局到長期價值：PBF 健康壽命策略推進 57
Slide 58: Milestones and 2026 catalyst calendar
1760.TT Since Last IR 依Milestone，穩步推進 ① 里程碑逐一兌現 CHG 擦澡組 PLLA 微球保媄妍平滑線平鎮二期關鍵臨床完成查登送件 11/11 17/45cm 完工量產 2026/7底前送件近期領證上市已上市保健&藥妝廠產擴大兩倍 ② 2026 催化劑日曆、醫美(逆齡、凍齡)全面布局 2026/5 2026/7 2026/9 2026/10 2026/12 雕塑線 17/45cm 珍珠水光美白/除皺微針眼膜微針 PLLA 微球已上市規劃上市規劃上市規劃上市取證目標 Section Update · Catalysts Safe H
Slide 59: Super-aged society: prevention and anti-aging
1760.TT PBF 2026 第一次法人說明會一個人口浪潮,兩端變現超高齡社會下的 PBF —— 疾病預防 × 無病抗老 20.06% 感染控制失能臥床 · 長照 · 院內感染 65 歲以上人口占比 · 2025 年底台灣正式邁入超高齡社會（內政部）醫美抗衰老抗老凍齡意識抬升
Slide 60: Anti-Aging Platform
1760.TT Anti-Aging Platform 同一浪潮的另一端-醫美抗衰老市場老化 → 抗老凍齡意識抬升，市場結構性成長醫美抗衰老端 • 變老 → 抗老凍齡意識抬升 • PLLA、外泌體+PRP、雕塑線、微針 • 台灣醫美市場規模突破 600億元 (含自費醫美手術：隆乳、抽脂、整型) 同一個人口趨力，往醫美這端推升的是『抗老凍齡』需求。 Anti-Aging · Medical Aesthetics Safe Harbor Statement Applies.
Slide 61: Depth-based Portfolio
1760.TT Depth-based Portfolio 以「深度」組織產品線表層凍齡（非侵入）→ 中胚層（再生）→ 深層逆齡（侵入）表層 · 微針平台 WSP 美白/除皺微針、SMP 偽髮（196 needles/cm²）中胚層 · 再生醫美外泌體+PRP（PxoBang）、多分子玻尿酸（珍珠水光）深層 · 微創醫美 PLLA 微米球（注射）、一體成形雕塑線（埋線） Anti-Aging · Medical Aesthetics Safe Harbor Statement Applies.
Slide 62: Deep layer: PLLA microspheres and sculpting threads
1760.TT Deep Layer — Minimally Invasive 深層：PLLA 微米球 + 一體成形雕塑線技術差異化｜國產自有專利 PLLA 微米球（皮膚填補劑）保媄妍® 一體成形雕塑線 SEM 電子顯微鏡圖電子顯微鏡下的微球體圖片 (左一及中間圖片:PLLA微球體的表面呈光滑狀; 右一圖片:當切開PLLA微球體時，內部結構為實心光滑之剖面) • 微球 30–100µm，表面光滑、內部實心 • 一體成形鑄模 >38.2N，優於切割/壓印 • 全層次施打，淺層至深層皆適用 • 雙鉤針、0.15 mm 等距間距→ 全臉拉力分布最均勻 Anti-Aging · Medical
Slide 63: Hero Product: exosome + PRP and multi-molecular hyaluronic acid
1760.TT Mid Layer — Regenerative Hero Product：外泌體 + PRP 與多分子玻尿酸中胚層再生醫美｜獨家標準化技術外泌體 + PRP（PxoBang）多分子玻尿酸（珍珠水光） • 活性保護技術（Double Umbrella）：目前唯一可室溫保存 • 專利分子切割技術:9 種分子量，皮膚上/中/ 3 年，確保活性穩定下各層全面補水 • 外泌體＋PRP 萃取技術：再生醫療獨有的雙效凍晶粉，定性 • 非交聯玻尿酸、無交聯劑殘留，降低交聯劑定量標準化殘留疑慮 Anti-Aging · Medical Aesthetics Safe Harbor
Slide 64: Surface layer: microneedle platform
1760.TT Surface Layer — Microneedle 表層：微針平台,模組化標靶層先進鑄模製程｜一針兩體 – 疊加式雙重微針技術 196 needles/cm² 高密度矩陣，精準遞送 | 針尖(標靶層)+針體(載體層) 美白淡斑除皺拉提眼膜微針 196 needles · 2026/9 上市 81 needles · 2026/9 上市 2026/10 上市 Anti-Aging · Medical Aesthetics Safe Harbor Statement Applies.
Slide 65: Production Backbone
1760.TT Production Backbone 抗老市場的生產、擴產：成長的產能後盾平鎮廠二期已量產、產能倍增；三期擴建中二期 · 已完工正式量產三期 · 2026 Q3 起建照/招標 • 消費品產線（保健＋化妝） • 西藥原物料倉庫（PIC/S GMP） • 產能已放大 2 倍，外泌體與玻尿酸已量產 • 半固型製劑西藥廠＋醫材廠 • 主供：生活事業處＋抗衰事業處 • 醫材廠落成後，PLLA 轉回平鎮放大量產 • 產能領先佈局 →可支撐後續成長 • 2026/5 整地完成產能後盾：二期產能已倍增並預留成長餘裕, 產線就緒、可隨業務放量同步擴充 Anti-Aging
Slide 66: PBF healthy longevity strategy
從研發布局到長期價值：PBF 健康壽命策略推進 66
Slide 67: Infection Control (Hospital & LTC)
1760.TT Infection Control (Hospital & LTC) 寶齡感控市場的發展：高齡社會的隱形防線 20.06% ~6,500 億超高齡社會 · 2025 年底長照產業規模（推估） 65 歲以上占比（內政部）產業推估｜《創新照顧》人口老化 → 失能臥床與長照需求結構性放大 → 感染控制成為剛性需求。 Disease Prevention · Infection Control Safe Harbor Statement Applies.
Slide 68: CHG Technology Platform
1760.TT CHG Technology Platform 寶齡感控市場的核心：CHG 技術平台,多產品衍生同一核心成分 Chlorhexidine Gluconate 2%，多場景衍生 CHG 2% 擦澡組牙周凝膠皮膚消毒｜旗艦牙科｜已上市 CHG 2% 核心平台口腔抗炎漱洗液無酒精照護｜已上市從『產品清單』升級為『技術平台』——同一核心，跨皮膚、牙科、口腔多場景衍生。 Disease Prevention · Infection Control Safe Harbor Statement Applies.
Slide 69: Market: 3 layers of need
1760.TT Market — 3 Layers of Need 擦澡巾的市場, 三層需求由專業院內，逐層擴散至居家院內感染防線醫院 ①術前 ②術後 ③加護病房(ICU)緊急消毒處置手術人次每年約 231 萬人〔衛福部，2024年〕市場逐層放大長照機構照護慢性重症長期臥床病患清潔消毒平均住院 9.29 天〔衛福部統計處, 2024年〕居家照護市場專業信任建立後，放大消費／居家市場由內而外的滲透機會院內 → 長照 → 居家，不是三個孤立市場，而是一條滲透路徑。 Disease Prevention · Infection Control Safe Harbor St
Slide 70: Q&A
Q&A Thank you for your attention. ir@pbf.com.tw Panion & BF Biotech Inc.

Panion & BF Biotech — Investor Presentation (June 2026) on 6ix

Panion & Bf Biotech — Investor Presentation (June 2026)

Slide 1: Health, Sharing, and Care

Slide 2: Disclaimer

Slide 3: Panion & BF Biotech Inc.

Slide 4: Content

Slide 5: Content

Slide 6: Financial Statements

Slide 7: Consolidated financial results 2023-2026 Q1

Slide 8: Revenue by segment

Slide 9: 2026 Q1 vs 2025 Q1 comparison

Slide 10: Q1 revenue by segment

Slide 11: PBF ESG

Slide 12: 2025 greenhouse gas inventory

Slide 13: 2025 sustainability report

Slide 14: IFRS sustainability disclosure adoption

Slide 15: PBF Key Business Units and Outlook

Slide 16: PBF growth framework: three growth engines

Slide 17: PBF healthy longevity strategy

Slide 18: PBF healthy longevity strategy

Slide 19: Innovative Medicine

Slide 20: Nephoxil China Approval

Slide 21: China Market Potential

Slide 22: Business Model Evolution

Slide 23: Ferric Citrate Japan

Slide 24: Ferric Citrate USA

Slide 25: Asia Pacific Market Expansion

Slide 26: New Drug Pipeline

Slide 27: PBF healthy longevity strategy

Slide 28: Diagnostic Division

Slide 29: IVD Development Status 2025-2027

Slide 30: Global IVD Approval Status

Slide 31: Pathogens of various kinds

Slide 32: Signals in the blood

Slide 33: Shortage of healthcare providers

Slide 34: Decentralization

Slide 35: Point of Care Test and Self Test

Slide 36: Diagnostic Delay and Comorbidities

Slide 37: Diagnostic delay and comorbidity by disease

Slide 38: Streamline the workflow from diagnosis to medical decision

Slide 39: Detection technology platforms

Slide 40: NANA HT (prototype)

Slide 41: Self-applied blood collection device

Slide 42: VSTRIP respiratory panel

Slide 43: Application Scenario

Slide 44: Clinic-Based POCT

Slide 45: Clinic-Based POCT

Slide 46: Home-Based Care

Slide 47: Disaster Medicine & Humanitarian Aid

Slide 48: Public Health Trend Analysis

Slide 49: Public Health Trend Analysis

Slide 50: Public Health Trend Analysis

Slide 51: Home Testing & Health Monitoring

Slide 52: Our POCT Ecosystem

Slide 53: Test reagents, instruments, data management

Slide 54: Diagnosis within minutes

Slide 55: Streamline the workflow from diagnosis to medical decision

Slide 56: VstriO AGE

Slide 57: PBF healthy longevity strategy

Slide 58: Milestones and 2026 catalyst calendar

Slide 59: Super-aged society: prevention and anti-aging

Slide 60: Anti-Aging Platform

Slide 61: Depth-based Portfolio

Slide 62: Deep layer: PLLA microspheres and sculpting threads

Slide 63: Hero Product: exosome + PRP and multi-molecular hyaluronic acid

Slide 64: Surface layer: microneedle platform

Slide 65: Production Backbone

Slide 66: PBF healthy longevity strategy

Slide 67: Infection Control (Hospital & LTC)

Slide 68: CHG Technology Platform

Slide 69: Market: 3 layers of need

Slide 70: Q&A